Back Holst, JJ (2022) 'Discovery of the GI effects of GLP-1: An historical perspective', Digestive Diseases and Sciences , 67, 2716-20
Broadened Therapeutic Applications: Emerging evidence suggests that microdosing GLP-1 RAs might benefit conditions beyond diabetes and obesity, such as: Cognitive decline Arthritis Metabolic dysfunction Immune function Cardiovascular health Improved Cost-Effectiveness: Using less medication may lower treatment costs
Do not self-administer retatrutide based on this chart
Lets, uh, yeah, not open that January 5th
GLP-1 receptor agonists should not be combined with DPP-4 inhibitors , as both act on the incretin pathway
Strikingly, these favorable features conferred by QMP were independent of the presence of a C-terminal L585